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Abstract 
 
Introduction: Continuous-flow left ventricular assist device (CF-LVAD) patients require warfarin, 
a vitamin K antagonist, as an anticoagulant to prevent thromboembolic events. LVAD patients 
that present with bleeding requiring a non-emergent procedure (ie. endoscopy) often require 
an international normalized ratio (INR) <2 to avoid potential procedural bleeding complications. 
The efficacy of high-dose intravenous (IV) vitamin K has been established for emergent INR 
reversal, but there are currently no studies that compare efficacy and safety of low-dose IV 
vitamin K (<5 mg) to “watchful waiting” for procedural, non-emergent INR reversal.  
 
Hypothesis: Low-dose IV vitamin K (<5 mg) will be as safe and more effective compared to 
“watchful waiting,” for INR reversal in patients presenting with non-emergent bleeding or in 
need of invasive procedures. 
 
Methods: We conducted a single-center, retrospective cohort analysis comparing low-dose IV 
vitamin K to “watchful waiting” in 121 LVAD patients. Baseline characteristics such as LVAD 
type, baseline INR (median and IQR), and vitamin K dose were collected. Primary endpoints 
included thrombotic and bleeding events within 90 days of discharge and number of patients 
with INR <2 within 24 hours of intervention. Secondary endpoints include procedural blood loss 
and length of hospital stay (days). Analyses was conducted using descriptive statistics, Fischer 
Exact, Mann-Whitney U, and chi-squared tests.  
 
Results: Patients in the IV vitamin K group had no thrombotic events compared to 23% of 
patients in the “watchful waiting” group (p=0.085). There were 38.5% and 11.8% bleeding 
event rates in the Vitamin K and “watchful waiting” groups, respectively (p=0.091). Patients 
receiving Vitamin K were more likely to have an INR <2 on days 1 and 2 compared to “watchful 
waiting” (p=0.046). From days 0 to 1, there was a decrease in median INR from 3.42 to 1.61 and 
2.47 to 2.17 in the Vitamin K and “watchful waiting” group respectively (p=<0.01). 
 
Conclusion: Using IV vitamin K to reverse warfarin prior to a non-emergent procedure was as 
safe as and more efficacious than “watchful waiting” alone. The major limitation of this study is 
its retrospective, non-randomized nature. Future prospective evaluation with a randomized 
controlled trial will be needed to corroborate these findings. 
 
Key Words: heart assist device, warfarin, international normalized ratio, anticoagulation  
Introduction 
 
There are approximately 2500 continuous-flow left ventricular assist device (CF-LVADs) 
implantations each year in the United States.1 Patients receiving CF-LVADs are at risk of 
developing pump thrombosis and require anticoagulation with warfarin, titrated to achieve a 
goal international normalized ratio (INR) of 2-3.2–5 Previous studies have demonstrated that 
patients with CF-LVADs spend less time in therapeutic range and are at an increased risk for 
bleeding and thrombotic complications.6,7 Bleeding is one of the most frequent complications 
with CF-LVADs occurring in 30% to 60% of patients that increase morbidity and mortality.8 In 
particular, gastrointestinal (GI) bleeding has been observed in up to 60% of patients and makes 
up 23% of the causes of 30-day readmission, making it the most common reason for hospital 
readmission in CF-LVAD patients.8 Thrombotic events are much less common with 2 year 
incidence rates ranging from 1.4% with HeartMate 3 and 6.4% with Heartware HVAD devices.8  
 
Beyond hematologic complications, patients with left ventricular assist devices are prone to 
other complications, some which require procedural intervention.9,10 Patients requiring 
procedural intervention may have prolonged stays in the hospital as providers allow a patient’s 
INR to drift down, a process called watchful waiting.  
 
To date, there have been limited studies evaluating the safety and efficacy of phytonadione 
(vitamin K) for patients with CF-LVADs. One study evaluated the efficacy of 100 mcg vitamin K 
with warfarin daily to help with INR control showing improved efficacy to reach therapeutic INR 
control.11 There have been no studies evaluating the safety and efficacy of low-dose vitamin K 
for the reversal of INR in patients with CF-LVADs. The objective of this study was to assess the 
safety and efficacy of low-dose (<5 mg) vitamin K for reversal of INR in patients presenting with 





This was a single center, retrospective cohort analysis evaluating the safety and efficacy of low-
dose vitamin K compared to watchful waiting. This study was approved by the Institutional 
Review Board. Patients were identified from the electronic health records (EHR). Patients were 
screened for a warfarin hold for a procedure and/or increased INR (> 4 and <10). Time of hold 
and reason for hold were collected. Patients were divided into two groups: low-dose vitamin K 
and watchful waiting. 
 
Patients were included if they had a CF-LVAD managed on warfarin, were admitted to undergo 
a non-life-threatening procedure that required interruption of their anticoagulation therapy, or 
had a supratherapeutic INR >4 and <10. Exclusion criteria included patients receiving vitamin K 
for a life-threatening complication (i.e. intracranial bleeding, blunt trauma), age <18, LVAD 
patients not managed on warfarin, cases of outpatient warfarin management complications 
(i.e. INR >4 not requiring hospital visit), and patients that died during the encounter not due to 
one of the primary or secondary endpoints.  
 
Data collected from the electronic medical record included demographic factors such as age on 
admission, race, and gender, LVAD type, serum creatinine, weight, height, presence of aspirin, 
presence of pentoxifylline, dipyridamole, or P2Y12 agent, length of stay, LDH, dose and route of 
vitamin K administered, procedure performed, INR on admission, INR on days 1, 2, and 3 after 
administration of vitamin K or watchful waiting, INR on discharge, thrombotic and bleeding 
events within 90 days after discharge, post-operative blood loss, and other products given (FFP, 
PRBC, Kcentra®). Missing INR values were interpolated using the Rosendaal method.12 
 
The objective of this study was to assess the safety and efficacy of low-dose vitamin K (<5 mg), 
for reversal of INR in patients presenting with non-emergent bleeding or in need of invasive 
procedures. The primary endpoints included thrombotic and bleeding events within 90 days of 
discharge as a measure of safety and percentage of patients with an INR <2 within 24 hours of 
intervention as a measure of efficacy. Thrombotic events included deep vein thrombosis (DVT), 
pulmonary embolism (PE), pump thrombosis, and/or myocardial infarction. Bleeding events 
included subdural hematoma, subarachnoid hemorrhage, GI bleed, or intracranial hemorrhage. 
Secondary endpoints included length of hospital stay (days) and operative blood loss (mL) as a 
measure of bleeding. 
 
Descriptive statistics were used to assess demographic factors, medications taken, pertinent lab 
values, and vitamin K doses and routes. The Mann-Whitney U test was used to analyze 
continuous non-parametric variables. The Fischer exact and chi-squared test was used to 
analyze categorical variables based on sample size. Data was reported as total counts and 
converted to percentages for each intervention or median with an interquartile range. Change 
in median INR between days 0,1,3, and discharge was assessed. Descriptive statistics were 
conducted in Microsoft Excel Version 2005 (Build 12827.20336) while all other analyses were 
conducted using R Studio Version 1.2.5001. A two-sided p-value of <0.05 was considered 





Patient Demographics and Study Population 
A total of 84 LVAD patients with 121 patient-encounters which required INR reversal were 
evaluated. After exclusions, there were 13 patient-encounters in the vitamin K group and 34 
patient-encounters in the watchful waiting group (Figure 1). Table 1 includes the baseline 
characteristics of the included patients. The median age of patients was 64 (IQR: 49-69) and 
59.5 (IQR: 48-64) for the vitamin K and watchful waiting group respectively. African American 
male patients make up a majority of study population with 53.8% and 47.1% in the treatment 
and control group respectively. Patients in the vitamin K group received either 1 mg (46.2%) or 
2 mg (53.8%) for INR reversal. Baseline INR was slightly higher in the treatment group (3.3) 
compared to the control group (2.1). Different low-dose vitamin K doses were utilized with 
46.2% being 1 mg IV and 53.8% being 2 mg IV. Concomitant medications included aspirin and 
pentoxifylline. 
 
Measure of Safety 
There were 0% and 23.5% thrombotic events (p = 0.085) in the vitamin K and watchful waiting 
group respectively (figure 2). Of the 8 thrombotic events in the watchful waiting group, 4 
patients experienced a stroke, 3 experienced pump thrombosis, and 1 experienced a DVT. 
There were 5 and 4 bleeding events in the vitamin K and watchful waiting groups respectively 
(38.5% and 11.8%, p = 0.091). All of the bleeding events in the vitamin K group were 
gastrointestinal. The 4 bleeding events in the watchful waiting group included subdural 
hematoma, subarachnoid hemorrhage, GI bleed, and intracranial hemorrhage.  
 
Measure of Efficacy 
The length of stay between the groups was assessed in 5-day intervals for up to 30 days (Figure 
3). In the vitamin K group, 38% of patients were discharged within 10 days and 21% in the 
watchful waiting group (p= 0.084). The number of days it took the INR to be <2 after 
intervention was assessed on days 0, 1, 2, 3, and at discharge (Figure 4). In the vitamin K group, 
92% of patients achieved an INR <2 on day 2 compared to 56% in the watchful waiting group 
(p= 0.046). An INR decrease of 3.42 to 1.61 in the vitamin K group and 2.47 to 2.17 in the 
watchful waiting group (p = <0.01) was observed from day 0 after intervention to day 1 (Figure 
5). The median INR on day 3 was 1.72 and 1.47 for the vitamin K and watchful waiting groups 
respectively with a p-value of 0.02. The median INR on discharge was 1.46 and 1.90 for the 





Thromboembolic and bleeding complications in LVAD patients are common. Non-emergent 
procedures such as endoscopies need INR reversal to prevent bleeding complications. Most 
cases target an INR <2 by holding warfarin and waiting for INR to come down to goal levels.2 
This can lead to increased length of hospital stay and infection risk leading to poor outcomes. 
Low-dose vitamin K has been hypothesized to decrease INR safely and effectively to reach goal 
INR levels faster. To our knowledge, this is the first study to evaluate safety and efficacy for the 
use of low-dose vitamin K for procedural INR reversal in LVAD patients. 
 
Balancing bleeding and thrombotic risk in patients taking warfarin has been a challenge. Using 
vitamin K for INR reversal has been associated with thrombotic events due to over-correction of 
INR.9 However, there was no significant increase in thrombotic events with low-dose vitamin K 
noted compared to watchful waiting suggesting less impact on INR over-correction . Though not 
significant, bleeding events occurred more in the low-dose vitamin K group. This may have been 
due to those patients being at higher risk for bleeding due to prior GI bleeding events. Previous 
studies have also shown variability in GI bleeding with INR changes, suggesting slight variations 
in bleeding risk with lower INR values depending on the patient.3 Operative blood loss was not 
assessed due to lack of reporting. Only 12 encounters between the groups reported operative 
blood loss making it difficult to analyze and assess the impact it may have had on bleeding. 
Based off the thrombotic and bleeding events noted, it can be suggested that the safety of low-
dose vitamin K is comparable to watchful waiting. 
 
Non-emergent procedures generally ask for an INR <2 to prevent excessive bleeding during the 
procedure. Patients receiving low-dose vitamin K achieved an INR <2 more quickly compared to 
the watchful waiting group (p=0.046). Thus, the results show that within 1 day of low-dose 
vitamin K administration, patients have lowered the INR to <2 allowing them to proceed with 
the procedure indicated and showing efficacy. However, length of hospital stay was not 
impacted (p=0.08) potentially due to a small sample size and complications of patients. Many 
patients required a non-emergent procedure but had to stay in the hospital afterwards for 
treatment. Other patients developed complications such as infections during their hospital 
course, requiring prolonged hospitalizations. Therefore, although low-dose vitamin K decreases 
time to procedure, the impact it has on overall hospital stay is limited. A more stable patient 
population stratified based off of comorbidities and complications can better assess length of 
hospitalization in a future study. 
 
Limitations include small sample size, single-center experience, and retrospective study design. 
Due to the small sample size, it was difficult to balance comparator group for demographic 
factors, introducing confounding bias. The small sample size may have also contributed to a 
type II error suggesting some of the data may be significant if there were more samples. With 
these limitations, we suggest a prospective, randomized controlled trial powered for the 
primary endpoints of safety and efficacy. To increase study power for a prospective study, the 
number of vitamin K patients can be increased by lengthening study dates since low-dose 
vitamin K administration has become more prevalent at UNC Medical Center. 
 
In conclusion, the data suggests vitamin K to be safe and effective for procedural INR reversal 
compared to watchful waiting in the LVAD population. A prospective, randomized, controlled 
study between low-dose vitamin K and watchful waiting is warranted to confirm the safety and 
efficacy of vitamin K.  
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INR = international normalized ratio; IV = intravenous; mg = milligrams  
121 patient encounters 
47 patient encounters (13 in vitamin K and 34 in 
watchful waiting) included in analyses 
74 encounters excluded 
• 46: INR > 4 outpatient 
• 7: Emergent bleeding from trauma 
• 6: IV vitamin K > 5 mg 
• 4: Died at end of encounter not due to 
endpoints 
• 4: INR trending up quickly (< 4 mg) 
• 3: Encounter past study range 
• 3: By mouth vitamin K used 
• 1: INR held for frequent hospital visits 
Table 1: Patient Baseline Characteristics, n = 47 
  Vitamin K 
N = 13 
Watchful 
Waiting 
N = 34 
P-value 
Median Age on admission, years 
(IQR) 
64 (49-69) 59.5 (48-64) 0.512 
Race, n (%) 
  
0.840 
     Caucasian 5 (38.5) 15 (44.1)  
     African American 7 (53.8) 16 (47.1)  
     Other 1 (7.7) 3 (8.8)  
Gender, n (%) 
  
0.257 
     Male 13 (100.0) 28 (82.4)  
     Female 0 (0.0) 6 (17.6)  




     Aspirin 7 (53.8) 17 (50.0) 
     Pentoxifylline 3 (23.1) 3 (8.8)  
LVAD Type, n (%) 
  
0.995 
     HeartMate II™ 5 (38.5) 13 (38.2)  
     HeartMate III™ 6 (46.2) 15 (44.1)  
     HeartWare HVAD® 2 (15.4) 6 (17.6)  
Baseline LDH (mg/dL),  
median (IQR) 
573 (483-742) 748 (610-1069) 0.026 
Baseline INR, median (IQR) 3.3 (2.7-4.5) 2.1 (1.6-3.1) 0.020 
vitamin K dose, n (%) 
  
<0.01 
     1 mg IV 6 (46.2) N/A  
     2 mg IV 7 (53.8) N/A  
IQR = interquartile range; n = event frequency; LDH = lactate dehydrogenase; INR = 
international normalized ratio; IV = intravenous; mg = milligrams; p <0.05 is significant 
 
  































Vitamin K Watchful Waiting
P = 0.085 
P = 0.091 













































Vitamin K Watchful Waiting
P = 0.084 














Day 1 Day 2 Day 3 Discharge
Vitamin K Watchful Waiting
P = 0.046 
Figure 5: Median Change in INR from Admission to Discharge Between vitamin K and Watchful 
Waiting 
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